- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Here's a summary of Gem Aromatics' investor presentation:
**Business Performance:** Q1FY27 saw YoY revenue growth for Gem Aromatics, despite a seasonally softer quarter. The Clove business faced temporary headwinds due to floods in Madagascar impacting raw material prices. Consolidated profitability was affected by higher depreciation charges (~Rs 9.1 Cr) stemming from the recent capitalization of the ~Rs 265 Cr Dahej capex.
**Growth Drivers or Strategy:** Gem Aromatics is focusing on leveraging its expanded manufacturing platform at Dahej and scaling newer product categories like cooling agents and Safranal through Krystal Ingredients. The company is also strengthening its international presence with a planned subsidiary in Brazil to enhance its reach in Latin America.
**Recent Developments:** Customer audits for cooling agents (GEM Cool 03, 05, 23) are complete with initial orders secured, expecting revenue contribution from Q3FY27. Commercial production of Safranal is anticipated by the end of Q2FY27. Trial production for Phenol Derivatives is expected by end of Q2FY27, with commercial production targeted for Q3FY27.
**Key Financial Metrics:** Consolidated revenue grew 13% YoY to Rs 98.9 Cr. However, consolidated PAT declined 199% YoY to a loss of Rs (7.9) Cr, largely due to higher depreciation. Standalone revenue grew 9% YoY to Rs 83.0 Cr, with PAT up 11% YoY to Rs 7.3 Cr.
**Management Commentary / Outlook:** Management highlights progress in customer engagement and product qualification, aiming to convert these into recurring commercial business. Innovation and R&D remain central, focusing on process improvements and higher-value specialty molecules. The Dahej facility's multipurpose capabilities offer flexibility for evolving customer needs. The company is committed to disciplined execution and sustainable value creation.